Although PD-L1 expression on tumor cells has been shown to be correlated with response to anti-PD-1 axis targeted therapies, not all PD-L1-positive patients benefit from such therapies; on the other hand, some PD-L1-negative patients do respond. This evidence concerns the gene PDCD1 and neoplasm.